Status:

COMPLETED

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Lead Sponsor:

Tampere University

Conditions:

Prostate Cancer

Eligibility:

MALE

18-70 years

Phase:

PHASE4

Brief Summary

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers
  • Patients who are scheduled for radical prostatectomy with curative intents

Exclusion

    Key Trial Info

    Start Date :

    October 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 1 2006

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT00293696

    Start Date

    October 1 2004

    End Date

    November 1 2006

    Last Update

    May 8 2007

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    TUCH

    Tampere, Finland, 33521

    Casodex/Zoladex Biomarkers in Localised Prostate Cancer | DecenTrialz